Multiple factors influence the survival of disseminated breast tumour cells (DTCs) in bone.
Introduction

21
The process of metastatic spread from the primary breast tumour to bone is undoubtedly 22 inefficient, with less than 0.01% of tumour cells released into the circulation able to form bone 23 metastases (Cameron, et al. 2000) . Multiple factors influence the success or failure of these 24 tumour cells, including their intrinsic properties and the myriad of environmental factors 25 encountered on the journey from breast to bone. Gene signature studies have identified genes 26 that predict a propensity of tumours to metastasise to bone, including CAPG, GIPC1, TFF1 (Smid, 27 et al. 2006; Westbrook, et al. 2016 ), but whilst these have a predictive value they cannot 28 determine bone related disease outcomes for individual patients and are therefore not yet 29 utilised in the clinical setting. The environment plays an important role in determining the fate 30 of tumour cells; they have to overcome shear forces and oxidative stress in the circulation 31 before extravasating (Massague and Obenauf 2016) , once in the bone microenvironment they 32 are vulnerable to immune surveillance. There is evidence that breast cancer cells locate to 33 specific niches within the bone microenvironment that will support their survival, using 34 chemokine receptors such as CXCR4 to select for areas of ligand (CXCL12, also known as SDF-1) 35 rich bone marrow (Muller, et al. 2001) . Tumour cells secrete various factors to modify this new 36 environment and promote their survival, supporting dormancy and recurrence years after the 37 primary tumour (Kang and Pantel 2013) . Adjuvant therapy after removal of the primary breast 38 tumour aims to reduce the risk of tumour recurrence by targeting single cell/small volume 39 micrometastases that have not yet acquired the ability to sustain autonomous growth.
40
However, it is now recognized that these small volume disseminated tumor cells (DTCs) may be 41 in a non-proliferative state and not responsive to anti-proliferative agents (Massague and less hospitable and thereby promote tumour cell death. The bone-targeting bisphosphonates 45 have been evaluated in large phase III adjuvant breast cancer trials and trials are ongoing with 46 the newer agent denosumab. Both types of agents target the bone resorbing osteoclast (Oc).
47
The bisphosphonate trials showed an interesting interplay between the prevailing endocrine 48 environment and the efficacy of bisphosphonates; only women with postmenopausal levels of 49 ovarian hormones (natural or chemically induced with the ovarian suppressor goserelin) showed 50 improvements in disease outcomes with addition of bisphosphonates to standard adjuvant 51 therapy (Coleman, et al. 2015) . This suggests that the endocrine influence on bone creates two 52 distinct bone microenvironments (pre-vs postmenopausal) that differentially affect DTCs within 53 them and influence therapies that target the bone resorbing Ocs.
55
Tumour dissemination to bone and the bone microenvironment 56 Bone metastases from breast cancer are currently incurable with a median survival of 2.3 years 57 following diagnosis (Harries, et al. 2014) . The formation of clinically evident bone metastases 58 represents the final part of a process of interactions between tumor cells and bone cells that 59 may have lasted decades in patients who experience disease relapse many years after surgical 60 excision of their primary tumour. Disseminated tumour cells (DTCs) are found in the bone 61 marrow of a third of patients and 50% of these will develop metastatic disease during the first 62 10 years post diagnosis (Braun, et al. 2005) . Thus the presence of DTCs confers a poorer 63 prognosis, but there is also a significant proportion of patients in whom tumour cells reach the 64 bone marrow but do not develop into metastases, hence DTCs either die or are maintained in a resorption pits formed by the bone resorbing osteoclasts (Oc). The presence of tumour cells 69 alters the bone microenvironment, increasing numbers/activity of Oc and decreasing 70 numbers/activity of Ob, even prior to the development of overt bone lesions (Brown, et al. 71 2012) . These early interactions may influence the outcome for tumour cells, determining 72 whether they die, enter a dormant non-proliferative state or undergo early expansion to 73 macrometastases. It is now well recognized that tumour cell fate can be influenced by multiple 74 host factors within the bone microenvironment (see figure 1 ).
75
Osteoblasts and the haematopoetic stem cells (HSCs); In normal physiology HSCs function is to 76 contribute to haematopoesis for months or even a lifetime. They respond to extrinsic 77 (microenvironmental) signals to remain quiescent, to self-renew, or to undergo differentiation.
78
The dormant state may in part be controlled by the Ob with evidence that increasing the 79 number of Obs with parathyroid hormone (PTH) also increases the number of HSCs and the 80 number of DTCs from subcutaneous prostate tumours (Shiozawa, et al. 2011 ). These DTCs are 81 thought to be subject to the same Ob-derived signals that maintain HSC dormancy, thus 82 maintaining tumour cell survival and contributing to relapse in bone many years after the initial 83 diagnosis of the primary tumour. A recent study in mice has demonstrated that breast cancer 84 cells form heterotypic adherence junctions with osteoblastic cells, resulting in activation of 85 mTOR in the tumour cells and their proliferation to form micrometastases, implicating the 86 osteoblasts in early progression (Wang et al, 2015) . (Lim, et al. 2011) . miRNAs have further roles in metastases and 117 silencing of expression of miRNA-126 in breast cancer cells increased metastases to multiple 118 sites including bone by promoting endothelial cell recruitment to breast cancer cells (Png, et al. tumours and blood vessels (M2). Tumour associated macrophages (TAMs) are also able to limit 124 the effect of anti-cancer therapies by associating with tumour blood vessels and promoting 125 revascularization after chemotherapy in both primary breast tumours and bone metastases 126 (Hughes, et al. 2015) . In this study TAMS were attracted to these sites by the interaction of 
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including interleukins 1β and 6, TNFα (Kinder, et al. 2008) , which induce Ob and bone stromal 132 cells to secrete factors which attract more myeloid cells and perpetuate the pro-tumourigenic 133 effects by stimulating RANKL expression on Ob (Lam, et al. 2000) 
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changes the behavior of the cancer cells from an epithelial to a more invasive mesenchymal 143 phenotype, which may promote the spread of these cells to the bone (El-Haibi, et al. 2012) . In a 144 cohort of patients with oestrogen receptor (ER) negative (ER-) breast cancers, primary tumours 145 that showed up regulation of genes involved in tumour hypoxia, including LOX, was associated 146 with metastases to bone rather than lung, liver and brain (Cox, et al. 2015) , suggesting that LOX 147 may be involved in preferential homing of tumour cells to bone. A murine model of 148 spontaneous ER-ve breast cancers which express LOX showed that the appearance of focal 149 osteolytic lesions preceded the arrival of tumour cells in bone, suggesting that hypoxia-induced 150 tumour secreted factors, including LOX, 'primes' the bone to receive tumour cells through an 151 increase in Oc mediated bone resorption (Cox et al. 2015) . Numerous additional extracellular 152 matrix molecules are involved in the formation of a pre-metastatic niche, including periostin 153 (Wang 2016) , tenascin (Chiovaro 2015) (Perrien, et al. 2006 ). As menopause is characterised by a decrease in ovarian oestradiol and inhibins, with an increase in pituitary follicle stimulating 164 hormone (FSH), this review will focus on the role of these 3 key hormones. The role of other 165 hormones may also be important, with a recent study reporting a role for prolactin in the 166 development of breast cancer bone metastasis and the associated bone disease (Sutherland et 174 2001). Oestrogen also maintains the number and activity of HSCs in bone (Qiu, et al. 2012) , and 175 increases the ratio of OPG/RANKL (Yan and Ye 2015) . The ability of oestrogen to affect the bone 176 vasculature is not well described, but there is close association between osteogenesis and 177 vasculogenesis suggesting that modification of bone will influence vessels and vice versa. 17β-178 oestradiol can influence sub-cutaneous tumour vasculature, increasing vessel density and 179 maintaining a more structured vasculature (Pequeux, et al. 2012 ). The immune system can be 180 modified by oestrogen with evidence that oestrogen inhibits the secretion of pro-inflammatory 181 cytokines including IL-6, TNFα and macrophage inhibitory factor from monocytes mediated 182 through the ERα36 receptor on the surface of human peripheral monocyte (Pelekanou, et al. 183 2016) . Oestrogen also affects miRNA expression and CAFs with evidence that 17β-estradiol 184 induces miR144 expression resulting in down-regulation of the onco-suppressor Runx1 185 (Vivacqua, et al. 2015) .
Inhibins are not abundantly expressed in bone, but radiolabelled inhibin A administered 187 intravenously in vivo accumulates rapidly in the bone marrow (reviewed in Wilson et al) (Wilson, (Jeruss, et al. 2003) . Activin, secreted from monocytes and bone fibroblasts, has been 200 shown to suppress immune processes in bone (Abe, et al. 2002 ), suggesting the inhibin/activin 201 pathway may be important for bone specific immune /inflammatory processes.
203
Inhibins inhibit the secretion of follicle stimulating hormone (FSH) from the anterior pituitary. In 204 the previously discussed cross sectional study, FSH correlated with bone resorption markers 205 (CTX) but not bone formation markers (BSAP) in perimenopausal women only (Perrien et al. 206 2006) . In vivo treatment of ovariectomised 14-week old mice with an antibody to β-subumit of 207 FSH prevented OVX-induced bone loss after 4 weeks of treatment associated with increases in 208 bone formation and inhibition of bone resorption ). There is however reports 209 suggesting that lowering FSH increases bone resorption; a prospective study of changes in bone turnover in postmenopausal women (n=46) with inhibition of FSH, using GnRH agonists, showed 211 a significant increase in CTX and TRAP5b (serum markers of bone resorption) with suppression 212 of FSH, in addition to a significant increase in P1NP (a marker of bone formation) (Drake, et al. 213 2010), thus the specific effects of FSH on bone turnover still need to be defined. FSH has effects 214 on HSC in bone, with evidence from in vivo models that bone derived HSC express FSH receptor 215 and that treatment with FSH enhances haematopoetic recovery after chemotherapy (Shaikh, et 216 al. 2016) . FSH also influences the vasculature; the FSH receptor (not normally expressed on 217 vascular endothelium) is upregulated in the vasculature of bone metastases (Siraj, et al. 2013 ).
218
The influence of FSH on bone mass has also been linked to its effects on the immune system; 219 production of bone resorbing cytokines and BMD was evaluated in 36 healthy women (aged 20-220 50) and showed BMD was inversely proportional to FSH levels and endogenous FSH levels 221 correlated with circulating levels of IL-1beta, moreover, exogenous FSH induced isolated 222 monocytes to secrete IL-1beta, TNF-alpha, and IL-6 (Cannon, et al. 2010 ).
224
These data show that the endocrine hormones oestrogen, inhibin and FSH can modify multiple 225 components resulting in very different bone microenvironments in pre-and post menopausal 226 women. At the time of the final menstrual period (FMP), the majority of women will have 227 undetectable levels of inhibins (Burger, et al. 2002) however oestradiol remains detectable in 228 serum for up to 5 years (Burger, et al. 1999) . The rise in FSH can occur up to 3-10 years before 229 menopausal transition (Burger, et al. 2007 ), attributed to the decline in inhibins (Klein, et al. 230 2004) . The differing levels of endocrine hormones in pre-and postmenopausal women will 231 therefore exert differential effects on disseminated tumour cells (DTCs) in bone, with the 232 potential to modify both tumour growth and response to bone targeted therapy.
234
Endocrine effects on tumour cells in bone 235
In vivo the influence of endocrine hormones within the bone microenvironment in regulating 236 the fate of DTCs has been described. 12 week old BALB/c nude mice underwent ovariectomy 237 (OVX) and the bone microenvironment evaluated. Within 2 weeks post procedure the bone 238 microenvironment of OVX animals was significantly altered compared to sham animals with an 239 increase in Oc activity and decrease in Ob activity (Ottewell, et al. 2014) . This alteration in the 
244
bone may be less attractive for tumour cell homing it is more conducive to survival and growth 245 of cells that do colonise bone (Ottewell et al. 2014) . This data is supported by the results from 246 clinical studies evaluating disease recurrence in patients following a diagnosis of breast cancer.
247
Combined data on the incidence of bone marrow micrometastases in over 4,000 women 248 showed that premenopausal women had significantly higher incidence of bone marrow 249 micrometastases than postmenopausal women (32.7% vs 29.5% p=<0.001) (Braun et al. 2005) ,
250
indicating that premenopausal bone offers more favourable conditions for DTCs. A further 251 study evaluating the incidence of clinically overt bone metastases in over 7,064 women showed 252 the incidence to be significantly higher in younger women (Harries et al. 2014) suggesting that 253 premenopausal bone can support the growth of DTCs into bone metastases. Further data on 254 recurrence patterns of 6,792 breast cancer patients entered into trials conducted by the 255 International Breast Cancer Study Group showed that younger patients (<35 years) had 256 significantly higher incidences of bone metastases occurring during the course of their disease 257 (Colleoni, et al. 2000) . These data suggest that younger women may be at increased risk for bone metastases but how and which endocrine hormone is affecting the bone 259 microenvironment and DTCs is yet to be defined.
261
Endocrine influence on bone targeted therapies 262 Both preclinical and clinical studies have found that the anti-tumour efficacy of osteoclast-263 targeted agents is influenced by levels of endocrine hormones, with differential effects 264 according to menopausal status. These bone-targeted therapies have included bisphosphonates, 265 the RANKL inhibitor denosumab and the soluble decoy receptor OPG-Fc.
266
In vivo studies have shown that tumour growth in bone of 12-week old BALBc/nude mice 267 injected IC with the breast cancer cell line MDA-MB-231 was significantly decreased with 268 zoledronic acid (Zol) in animals who had undergone OVX (modeling postmenopausal) but not 269 sham-OVX (modeling premenopausal) (33% vs 86%). This effect on tumour cells was 270 independent of the effect of Zol on bone volume with drug-induced increases in both groups 271 and no significant difference in bone volume between Zol treated groups (Ottewell et al. 2014) .
272
This indicates that the effect of Zol on formation of bone metastases is independent of bone 273 volume but dependent upon other factors in the bone microenvironment that are differentially 274 affected by Zol according to the prevailing level of endocrine hormones. Further in vivo data has 275 supported an Oc mediated differential effect on breast cancer bone metastases according to 276 menopausal status using the potent inhibitor of osteoclastogenesis, OPG-Fc, which prevents Oc 277 activation by preventing RANKL-RANK binding similar in mechanism to denosumab (Ottewell, et MDA-MB-231 cells was decreased by OPG-Fc in OVX animals (7% vs 78.5%) but no effect was 281 seen in sham-OVX animals. These data suggest that pharmacological inhibition of Oc's decreases breast tumour growth in bones but only in a bone microenvironment that mimics 283 postmenopausal (OVX) with low levels of oestradiol and inhibin and high levels of FSH.
285
Clinical studies of adjuvant bisphosphonates for early breast cancer have included thousands of 286 patients treated with both oral and intravenous bisphosphonates. The largest of the zoledronic 287 acid studies included AZURE (n=3340) (Coleman, et al. 2011) , ABCSG-12 (n=1803) (Gnant, et al. 288 2011) and ZO-FAST (n=1065) (Coleman, et al. 2013) . AZURE recruited patients with a mixed 289 menopausal status; premenopausal (45%), unknown menopausal status (9.7%), <5 years since 
305
or delayed until evidence of bone mineral density (BMD) loss or fracture. The primary endpoint of this study was change in BMD at 12 months but pre-planned secondary analyses included DFS 307 and OS. Patients who started zoledronic acid with letrozole had a 34% decrease in DFS events 308 (HR 0.66 95%CI 0.44-0.97 p=0.0375) and exploratory analyses according to menopausal status at 309 randomisation showed that women >5 years postmenopausal or >60 years has a substantially 310 improved OS with early vs delayed zoledronic acid (HR 0.5; p=0.0224). This effect was not seen 311 in women who were recently postmenopausal due to chemotherapy induced ovarian toxicity, 312 oophorectomy or ovarian suppression. These trials indicated that adjuvant zoledronic acid was 313 able to improve disease outcomes only when started in women who had a very suppressed 314 hypothalamic-pituitary-gonadal (HPG) axis either naturally or chemically. Similar results were 315 reported with the adjuvant clodronate trials (Paterson, et al. 2012; Powles, et al. 2006 ) and a 316 large meta-analysis of all adjuvant bisphosphonate trials involving >18,000 breast cancer 317 patients has recently reported and showed that women who were postmenopausal at initiation 318 of bisphosphonates had fewer recurrences in bone (RR 0.72, 0.60-0.86; 2p=0.0002), at other 319 distant sites (RR 0.82, 0.74-0.92; 2p=0.0003) and an improved breast cancer mortality (RR 0.82, 320 0.73-0.93; 2p=0.002) (Coleman et al. 2015) . Inhibiting Oc's by inhibiting the RANKL-RANK 321 interaction is currently being evaluated in phase III trials of the RANK ligand inhibitor 322 denosumab and recent data from the ABCSG-18 trial has shown that adjuvant denosumab 323 reduces the risk of disease recurrence in postmenopausal patients with early stage hormone 324 receptor positive breast cancer , suggesting that osteoclast inhibition with an 325 alternative pharmacological agent to bisphosphonates also improves outcomes in patients with 326 a quiescent HPG axis. Further data is awaited from the D care study, which is a phase III trial 327 evaluating addition of denosumab to standard adjuvant therapy for 5 years in pre-and 328 postmenopausal women to define the population of patients who will derive most benefit.
330
Summary
331
It is evident that endocrine hormones play a key role in modifying multiple cells within the bone 332 microenvironment, including bone cells, immune cells, stromal cells and the vasculature, as well 333 as systemic factors and extracellular matrix components (Holen I 2016a) . This plethora of 334 cellular effects will undoubtedly have an influence on the homing to and survival of DTCs within 335 the bone microenvironment, with evidence to suggest this process is enhanced in a 336 premenopausal bone microenvironment with high oestradiol and inhibin and low FSH. The 337 clinical utility of Oc inhibitors, used in early breast cancer, with the aim to prevent bone 338 metastases and improve disease outcomes (DFS and OS) has been confirmed in a meta-analysis 339 of large phase III clinical trials involving thousands of women (Coleman et al. 2015) . These trials 340 have shown that inhibition of the Oc is only effective in preventing metastases when there is a 341 suppressed HPG axis, either due to natural menopause or chemically induced with GnRH 342 analogues. The challenge now is to understand the molecular mechanisms behind this 343 phenomenon and to evaluate if alternative bone targeted therapies, which act on other cellular 344 components of the bone microenvironment, may be effective in premenopausal women where 345 there is a clear need for bone targeted adjuvant therapy.
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Figure 2. Breast tumor cells visualized in close proximity to osteoblasts and blood vessels in mouse bone
Genetically engineered mice with GFP-expressing osteoblasts injected via the intracardiac route with CMDii-labelled human MDA-MB-231 cells before sample collection and processing for paraffin sections. Histological sections of tibias were stained with markers for endothelial cells using antibodies and DNA was visualized using DAPI. Tumor cells, osteoblasts and blood vessels were seen in close proximity to each other within the bone marrow compartment.
